U.S.C. homeSearch U.S. Code
U.S. CodeTitle 18Part I— CrimesChapter 31— Embezzlement and Theft

18 U.S.C. § 670 (2026)

Theft of medical products

Edition and currency
U.S. Code current through Pub. L. 119-102 (OLRC release point). The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTU.S. Code current through Pub. L. 119-102 (OLRC release point) ACTIVE · 3 IN 5Y cited 2013–2026 9citing cases
At a glance

Courts have cited this section in 9 opinions since 2013, 3 of them in the last five years.

(a)Prohibited Conduct.—Whoever, in, or using any means or facility of, interstate or foreign commerce—(1) embezzles, steals, or by fraud or deception obtains, or knowingly and unlawfully takes, carries away, or conceals a pre-retail medical product;(2) knowingly and falsely makes, alters, forges, or counterfeits the labeling or documentation (including documentation relating to origination or shipping) of a pre-retail medical product;(3) knowingly possesses, transports, or traffics in a pre-retail medical product that was involved in a violation of paragraph (1) or (2);(4) with intent to defraud, buys, or otherwise obtains, a pre-retail medical product that has expired or been stolen;(5) with intent to defraud, sells, or distributes, a pre-retail medical product that is expired or stolen; or(6) attempts or conspires to violate any of paragraphs (1) through (5);shall be punished as provided in subsection (c) and subject to the other sanctions provided in this section.(b)Aggravated Offenses.—An offense under this section is an aggravated offense if—(1) the defendant is employed by, or is an agent of, an organization in the supply chain for the pre-retail medical product; or(2) the violation—(A) involves the use of violence, force, or a threat of violence or force;(B) involves the use of a deadly weapon;(C) results in serious bodily injury or death, including serious bodily injury or death resulting from the use of the medical product involved; or(D) is subsequent to a prior conviction for an offense under this section.(c)Criminal Penalties.—Whoever violates subsection (a)—(1) if the offense is an aggravated offense under subsection (b)(2)(C), shall be fined under this title or imprisoned not more than 30 years, or both;(2) if the value of the medical products involved in the offense is $5,000 or greater, shall be fined under this title, imprisoned for not more than 15 years, or both, but if the offense is an aggravated offense other than one under subsection (b)(2)(C), the maximum term of imprisonment is 20 years; and(3) in any other case, shall be fined under this title, imprisoned for not more than 3 years, or both, but if the offense is an aggravated offense other than one under subsection (b)(2)(C), the maximum term of imprisonment is 5 years.(d)Civil Penalties.—Whoever violates subsection (a) is subject to a civil penalty in an amount not more than the greater of—(1) three times the economic loss attributable to the violation; or(2) $1,000,000.(e)Definitions.—In this section—(1) the term “pre-retail medical product” means a medical product that has not yet been made available for retail purchase by a consumer;(2) the term “medical product” means a drug, biological product, device, medical food, or infant formula;(3) the terms “device”, “drug”, “infant formula”, and “labeling” have, respectively, the meanings given those terms in section 201 of the Federal Food, Drug, and Cosmetic Act;(4) the term “biological product” has the meaning given the term in section 351 of the Public Health Service Act;(5) the term “medical food” has the meaning given the term in section 5(b) of the Orphan Drug Act; and(6) the term “supply chain” includes manufacturer, wholesaler, repacker, own-labeled distributor, private-label distributor, jobber, broker, drug trader, transportation company, hospital, pharmacy, or security company.(Added Pub. L. 112–186, § 2(a), Oct. 5, 2012, 126 Stat. 1427.)Editorial NotesReferences in Text

Section 201 of the Federal Food, Drug, and Cosmetic Act, referred to in subsec. (e)(3), is classified to section 321 of Title 21, Food and Drugs.

Section 351 of the Public Health Service Act, referred to in subsec. (e)(4), is classified to section 262 of Title 42, The Public Health and Welfare.

Section 5(b) of the Orphan Drug Act, referred to in subsec. (e)(5), is classified to section 360ee(b) of Title 21.

Statutory Notes and Related SubsidiariesPriority Given to Certain Investigations and Prosecutions

Pub. L. 112–186, § 4(e), Oct. 5, 2012, 126 Stat. 1429, provided that: “The Attorney General shall give increased priority to efforts to investigate and prosecute offenses under section 670 of title 18, United States Code, that involve pre-retail medical products.”

The 9 cases that cite 18 U.S.C. § 670 most heavily, weighted by court and treatment. RelevanceNewestTreatment
1
GREENRoberts v. State, 847 S.E.2d 541 (Ga. 2020).
cites § 670 10×cited by 7 cases
Where it cites § 670
“That offense, to which Roberts pled guilty in federal court on June 1, 2017, was for violating 18 USC § 670 (“Theft of medical products”).”
Later courts cite it for
“the denial of a statutory double jeopardy claim is appealable under the collateral order doctrine,” · 1 citing court
2
GREENUnited States v. Timothy Ritchie, 858 F.3d 201 (4th Cir. 2017).
cites § 670 2×cited by 38 cases
Where it cites § 670
“§ 1365 ] (relating to tampering with consumer products); or (iv) an offense under [ 18 U.S.C. § 670 ] (relating to theft of medical products); and (B) in which an identifiable victim or victims has suffered a physical injury or pecuniary loss.”
The case’s holding
The determination of whether an offense is against property under the Mandatory Victims Restitution Act is governed by the actual facts of the offense rather than the categorical approach.
Later courts cite it for
“congress could not have intended to exclude from the broad, mandatory reach of the mvra those unfortunate victims who suffer property loss as a result of an offense that doesn't contain as an element a reference to 'property.” · 5 citing courts
3
GREENUnited States v. Servando Alvarado-Casas, 715 F.3d 945 (5th Cir. 2013).
cites § 670 1×cited by 90 cases
The case’s holding
To establish plain error regarding a guilty plea, a defendant must show the error was clear or obvious and that a reasonable probability exists that the error affected voluntariness.
Later courts cite it for
“an error is plain, in this context, if it is 'clear or obvious' what the government must prove to establish the offense, and, notwithstanding that clarity, the district court accepts a defendant's guilty plea without an adequate factual basis.” · 5 citing courts
4
REDUnited States v. Xiulu Ruan, 966 F.3d 1101 (11th Cir. 2020).
cites § 670 1×cited by 21 cases
Flagged on editorial review. Vacated by Xiulu Ruan v. United States (2022): the U.S. Supreme Court's own opinion in this case.
Where it cites § 670
“§ 1365 ; or (4) an offense under 18 U.S.C. § 670 . Id. § 3663A(c)(1)(A)(i)–(iv).”
Later courts cite it for
“the relevant inquiry in making this determination is whether a reasonable jury could have found the jurisdictional element to have been satisfied beyond a reasonable doubt” · 2 citing courts
5
NO FLAGUnited States v. McCreless, No. 23-20482 (5th Cir. Aug. 26, 2024).
cites § 670 3×cited by 0 casesunpublished
Where it cites § 670
“1 if: his offense involved conduct described in 18 U.S.C. § 670 (prohibiting theft and illicit trafficking of pre-retail products); and he worked for an organization in the “supply chain” for a “pre-retail medical product”.”
6
NO FLAGUnited States v. Calh Holding Corp., No. 21-13593 (11th Cir. May 5, 2026).
cites § 670 3×cited by 0 casesunpublished
Where it cites § 670
“18 U.S.C. § 670 (a)(1). “Pre-retail medical product” means “a medical product that has not yet been made available for retail purchase by a consumer.”
7
NO FLAGUnited States v. Alvin Watts, III, No. 19-30407 (5th Cir. Aug. 14, 2020).
cites § 670 1×cited by 0 casesunpublished
Where it cites § 670
“§§ 371 & 2; trafficking in stolen and embezzled pre-retail medical products, in violation of 18 U.S.C. § 670 (a)(3), * Pursuant to 5TH CIR.”
8
NO FLAGGallardo v. United States, No. 1:18-cv-00802 (D.N.M. Mar. 27, 2020).
cites § 670 1×cited by 0 casesunknown
Where it cites § 670
“Gallardo also pled guilty to theft of medical products in violation of 18 U.S.C. §§ 670 , which was added by a separate Information.”
9
NO FLAGGallardo v. United States, No. 1:18-cv-00802 (D.N.M. June 29, 2021).
cites § 670 1×cited by 0 casesunknown
Where it cites § 670
“Gallardo also pled guilty to theft of medical products in violation of 18 U.S.C. §§ 670 , which was added by a separate Information.”

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
201320192026

One bar per year. Tallest: 4 cases in 2020. 2026 is a partial year. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
5th Cir.311th Cir.2D.N.M.24th Cir.1Ga.1
By subsection

Courts have not cited this section by subsection, so its cases are not split up here. The Leading cases tab lists the cases that cite it most heavily.

Enactment and amendments
(Added Pub. L. 112–186, § 2(a), Oct. 5, 2012, 126 Stat. 1427.)
Versions

Edition shown: U.S. Code current through Pub. L. 119-102 (OLRC release point). Syfert holds no earlier or later version of this section.

U.S.C. Home  |  Search U.S. Code  |  Search cases for this section  |  syfert.com